PL2593090T3 - Kompozycje farmaceutyczne modulatora c-Met - Google Patents
Kompozycje farmaceutyczne modulatora c-MetInfo
- Publication number
- PL2593090T3 PL2593090T3 PL11740764T PL11740764T PL2593090T3 PL 2593090 T3 PL2593090 T3 PL 2593090T3 PL 11740764 T PL11740764 T PL 11740764T PL 11740764 T PL11740764 T PL 11740764T PL 2593090 T3 PL2593090 T3 PL 2593090T3
- Authority
- PL
- Poland
- Prior art keywords
- pharmaceutical compositions
- modulator pharmaceutical
- met
- met modulator
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36525310P | 2010-07-16 | 2010-07-16 | |
US37084310P | 2010-08-05 | 2010-08-05 | |
EP11740764.3A EP2593090B1 (en) | 2010-07-16 | 2011-07-18 | C-met modulator pharmaceutical compositions |
PCT/US2011/044378 WO2012009722A1 (en) | 2010-07-16 | 2011-07-18 | C-met modulator pharmaceutical compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2593090T3 true PL2593090T3 (pl) | 2022-02-21 |
Family
ID=45469828
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL11740764T PL2593090T3 (pl) | 2010-07-16 | 2011-07-18 | Kompozycje farmaceutyczne modulatora c-Met |
Country Status (23)
Country | Link |
---|---|
US (9) | US9724342B2 (pl) |
EP (2) | EP4014971A1 (pl) |
JP (3) | JP5934204B2 (pl) |
KR (6) | KR20190042768A (pl) |
CN (3) | CN106420743A (pl) |
AR (1) | AR082252A1 (pl) |
AU (4) | AU2011278950C1 (pl) |
BR (1) | BR112013000980B1 (pl) |
CA (1) | CA2805645C (pl) |
DK (1) | DK2593090T3 (pl) |
EA (1) | EA030435B1 (pl) |
ES (1) | ES2904646T3 (pl) |
HU (1) | HUE057184T2 (pl) |
IL (2) | IL224189A (pl) |
LT (1) | LT2593090T (pl) |
MX (1) | MX336741B (pl) |
NZ (1) | NZ607118A (pl) |
PL (1) | PL2593090T3 (pl) |
PT (1) | PT2593090T (pl) |
SG (2) | SG10201609324UA (pl) |
TW (3) | TWI619495B (pl) |
WO (1) | WO2012009722A1 (pl) |
ZA (1) | ZA201300458B (pl) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200137052A (ko) | 2009-01-16 | 2020-12-08 | 엑셀리시스, 인코포레이티드 | 암의 치료를 위한 n-(4-{〔6,7-비스(메틸옥시)퀴놀린-4-일〕옥시}페닐)-n'-(4-플루오로페닐)사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형 |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
SG10201609324UA (en) | 2010-07-16 | 2017-01-27 | Exelixis Inc | C-met modulator pharmaceutical compositions |
EA027476B1 (ru) | 2010-09-27 | 2017-07-31 | Экселиксис, Инк. | Применение n-(4-{[6,7-бис-(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида для лечения кастрационно-резистентного рака простаты и остеобластических метастазов в кости |
ES2905571T3 (es) | 2011-02-10 | 2022-04-11 | Exelixis Inc | Procedimientos para la preparación de compuestos de quinolina y composiciones farmacéuticas que contienen dichos compuestos |
US20120252840A1 (en) * | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
EA029506B1 (ru) | 2011-05-02 | 2018-04-30 | Экселиксис, Инк. | Способ лечения рака и раковой боли в костях |
MX351133B (es) | 2011-09-22 | 2017-10-03 | Exelixis Inc | Metodo para tratar osteoporosis. |
EP2768796B1 (en) | 2011-10-20 | 2019-11-20 | Exelixis, Inc. | Process for preparing quinoline derivatives |
WO2013166296A1 (en) | 2012-05-02 | 2013-11-07 | Exelixis, Inc. | A dual met - vegf modulator for treating osteolytic bone metastases |
CN103664776B (zh) * | 2012-09-26 | 2016-05-04 | 正大天晴药业集团股份有限公司 | 一种酪氨酸激酶抑制剂及其中间体的制备方法 |
US10273211B2 (en) | 2013-03-15 | 2019-04-30 | Exelixis, Inc. | Metabolites of N-{4-([6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
EP2981263B1 (en) | 2013-04-04 | 2022-06-29 | Exelixis, Inc. | Cabozantinib dosage form and use in the treatment of cancer |
CN104370811B (zh) * | 2013-08-15 | 2019-02-12 | 广东东阳光药业有限公司 | 一种喹啉化合物的新晶型及其制备方法 |
CN104649969B (zh) * | 2013-11-22 | 2019-02-12 | 广东东阳光药业有限公司 | 一种替尼类药物的盐及其制备方法 |
CN103751140A (zh) * | 2014-01-15 | 2014-04-30 | 青岛市肿瘤医院 | 一种Cabozantinib分散片及其制备方法 |
AU2015218236B2 (en) | 2014-02-14 | 2019-06-13 | Exelixis, Inc. | Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use |
JP6666849B2 (ja) * | 2014-03-17 | 2020-03-18 | エグゼリクシス, インコーポレイテッド | カボザンチニブ製剤の投与 |
CN104788372B (zh) * | 2014-07-25 | 2018-01-30 | 上海圣考医药科技有限公司 | 一种氘代卡博替尼衍生物、其制备方法、应用及其中间体 |
ES2929888T3 (es) | 2014-07-31 | 2022-12-02 | Exelixis Inc | Procedimiento para preparar cabozantinib marcado con flúor 18 y sus análogos |
CA2957466C (en) | 2014-08-05 | 2023-10-17 | Exelixis, Inc. | Drug combinations to treat multiple myeloma |
CN105503717A (zh) * | 2014-09-24 | 2016-04-20 | 江苏奥赛康药业股份有限公司 | 一种苹果酸卡博替尼化合物及其药物组合物 |
US11141413B2 (en) | 2016-04-15 | 2021-10-12 | Exelixis, Inc. | Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate |
US20210030737A1 (en) * | 2016-04-19 | 2021-02-04 | Exelixis, Inc. | Triple Negative Breast Cancer Treatment Method |
EP3518928A1 (en) | 2016-09-27 | 2019-08-07 | The United States of America, as Represented by The Secretary, Department of Health and Human Services Office of Technology Transfer | Method of treating urothelial carcinoma and other genitourinary malignancies using n-(4-(6,7-dimethoxyquinolin-4-yloxy)-phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
EP3551612A4 (en) * | 2016-12-07 | 2020-08-12 | MSN Laboratories Private Limited, R&D Center | PROCESS FOR THE PREPARATION OF N- (4- (6,7-DIMETHOXYQUINOLIN-4-YLOXY) PHENYL) -N '- (4-FLUOROPHENYL) CYCLOPROPANE-1, 1-DICARBOXAMIDE, (2S) -HYDROXYBUTANYEDIOOR AND ITS POLYDROXYBUTANYMATE |
CN117205312A (zh) | 2017-01-20 | 2023-12-12 | 埃克塞里艾克西斯公司 | 治疗癌症的卡博替尼与阿特珠单抗组合 |
MX2019012505A (es) | 2017-05-26 | 2019-12-19 | Exelixis Inc | Formas solidas cristalinas de sales de ciclopropano-1,1-dicarboxam ida de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofen il), procesos para realizarlas y metodos de uso. |
CA3067044A1 (en) * | 2017-06-16 | 2018-12-20 | Beta Pharma, Inc. | Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof |
US20190262330A1 (en) * | 2017-12-21 | 2019-08-29 | Exelixis, Inc. | Method of Treating Hepatocellular Carcinoma Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate |
CA3088200A1 (en) | 2018-01-26 | 2019-08-01 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
EP3806858A4 (en) | 2018-06-15 | 2022-03-09 | Handa Pharmaceuticals, Inc. | SALTS OF KINASE INHIBITORS AND ASSOCIATED COMPOSITIONS |
WO2020075196A1 (en) * | 2018-10-11 | 2020-04-16 | Cipla Limited | Polymorphs of n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide, (s)- malate, methods of production and pharmaceutical uses thereof |
CR20220551A (es) * | 2020-04-30 | 2022-12-07 | Exelixis Inc | Procesos para la preparación de un inhibidor de cinasa |
JP2023548855A (ja) * | 2020-11-05 | 2023-11-21 | エグゼリクシス, インコーポレイテッド | キナーゼ阻害剤の医薬組成物 |
US11613630B2 (en) | 2020-12-03 | 2023-03-28 | Iowa State University Research Foundation | Solid dry-type lubricant |
WO2023122723A1 (en) | 2021-12-23 | 2023-06-29 | The Broad Institute, Inc. | Panels and methods for diagnosing and treating lung cancer |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003225668A1 (en) | 2002-03-01 | 2003-09-16 | Pintex Pharmaceutical, Inc. | Pin1-modulating compounds and methods of use thereof |
EP2210607B1 (en) | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer |
TWI347940B (en) | 2003-11-07 | 2011-09-01 | Novartis Ag | Methods for synthesizing quinolinone compounds |
ME02184B (me) * | 2003-12-25 | 2016-02-20 | Eisai R&D Man Co Ltd | KRISTALNI OBLIK SOLI 4 -(3-HLORO-4- (CIKLOPROPILAMINOKARBONIL)AMINO-FENOKSI)-7-METOKSI-6-HINOLINKARBOKSAMIDA lLI NJEGOVIH SOLVATA l PROCES ZA NJIHOVU PROIZVODNJU |
WO2006014325A2 (en) | 2004-07-02 | 2006-02-09 | Exelixis, Inc. | C-met modulators and method of use |
WO2006108059A1 (en) | 2005-04-06 | 2006-10-12 | Exelixis, Inc. | C-met modulators and methods of use |
CA2671982C (en) | 2006-12-14 | 2016-01-26 | Exelixis, Inc. | Methods of using mek inhibitors |
WO2008083319A1 (en) | 2006-12-29 | 2008-07-10 | Il Yang Pharmaceutical Company, Ltd. | Solid state forms of enantiopure ilaprazole |
UY31800A (es) | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
AR075084A1 (es) | 2008-09-26 | 2011-03-09 | Smithkline Beecham Corp | Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes |
WO2010056960A1 (en) | 2008-11-13 | 2010-05-20 | Exelixis Inc. | Methods of preparing quinoline derivatives |
JP2012511017A (ja) | 2008-12-04 | 2012-05-17 | エグゼリクシス, インコーポレイテッド | キノリン誘導体の調製方法 |
KR20200137052A (ko) | 2009-01-16 | 2020-12-08 | 엑셀리시스, 인코포레이티드 | 암의 치료를 위한 n-(4-{〔6,7-비스(메틸옥시)퀴놀린-4-일〕옥시}페닐)-n'-(4-플루오로페닐)사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형 |
KR20120051702A (ko) | 2009-07-17 | 2012-05-22 | 엑셀리시스, 인코포레이티드 | N-〔3-플루오로-4-({6-(메틸옥시)-7-〔(3-모르폴린-4-일프로필)옥시〕퀴놀린-4-일}옥시)페닐〕-n''-(4-플루오로페닐)시클로프로판-1,1-디카르복사미드의 결정형 |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
EP2475390A4 (en) * | 2009-09-09 | 2014-01-01 | Quintiles Transnat Corp | METHODS AND COMPOSITIONS FOR THE TREATMENT OF TYROSINE KINASE RECEPTOR MEDIATION DISEASES OR DISORDERS |
SG184040A1 (en) | 2010-03-12 | 2012-10-30 | Exelixis Inc | Hydrated crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
US20120070368A1 (en) | 2010-04-16 | 2012-03-22 | Exelixis, Inc. | Methods of Using C-Met Modulators |
SG10201609324UA (en) | 2010-07-16 | 2017-01-27 | Exelixis Inc | C-met modulator pharmaceutical compositions |
US20140186407A9 (en) | 2010-07-16 | 2014-07-03 | Exelixis Inc. | C-Met Modulator Pharmaceutical Compositions |
EA027476B1 (ru) | 2010-09-27 | 2017-07-31 | Экселиксис, Инк. | Применение n-(4-{[6,7-бис-(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида для лечения кастрационно-резистентного рака простаты и остеобластических метастазов в кости |
US20140066444A1 (en) | 2010-09-27 | 2014-03-06 | Exelixis, Inc. | Method of Treating Cancer |
CA2812744A1 (en) | 2010-09-27 | 2012-04-05 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases |
CN103327979A (zh) | 2010-11-22 | 2013-09-25 | 葛兰素史密斯克莱知识产权(第2号)有限公司 | 治疗癌症的方法 |
ES2905571T3 (es) | 2011-02-10 | 2022-04-11 | Exelixis Inc | Procedimientos para la preparación de compuestos de quinolina y composiciones farmacéuticas que contienen dichos compuestos |
US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
EA029506B1 (ru) | 2011-05-02 | 2018-04-30 | Экселиксис, Инк. | Способ лечения рака и раковой боли в костях |
TW201306842A (zh) | 2011-06-15 | 2013-02-16 | Exelixis Inc | 使用pi3k/mtor吡啶並嘧啶酮抑制劑及苯達莫司汀及/或利妥昔單抗治療惡性血液疾病之組合療法 |
EP2768796B1 (en) | 2011-10-20 | 2019-11-20 | Exelixis, Inc. | Process for preparing quinoline derivatives |
-
2011
- 2011-07-18 SG SG10201609324UA patent/SG10201609324UA/en unknown
- 2011-07-18 SG SG2013002704A patent/SG187060A1/en unknown
- 2011-07-18 AU AU2011278950A patent/AU2011278950C1/en active Active
- 2011-07-18 JP JP2013519870A patent/JP5934204B2/ja active Active
- 2011-07-18 KR KR1020197010923A patent/KR20190042768A/ko active Application Filing
- 2011-07-18 ES ES11740764T patent/ES2904646T3/es active Active
- 2011-07-18 TW TW105119659A patent/TWI619495B/zh active
- 2011-07-18 DK DK11740764.3T patent/DK2593090T3/da active
- 2011-07-18 CN CN201610157218.7A patent/CN106420743A/zh active Pending
- 2011-07-18 KR KR1020187014254A patent/KR20180056807A/ko active Application Filing
- 2011-07-18 KR KR1020207007177A patent/KR20200029633A/ko active Application Filing
- 2011-07-18 CA CA2805645A patent/CA2805645C/en active Active
- 2011-07-18 WO PCT/US2011/044378 patent/WO2012009722A1/en active Application Filing
- 2011-07-18 KR KR1020137003043A patent/KR101862324B1/ko active IP Right Review Request
- 2011-07-18 AR ARP110102584A patent/AR082252A1/es not_active Application Discontinuation
- 2011-07-18 PT PT117407643T patent/PT2593090T/pt unknown
- 2011-07-18 EP EP21202135.6A patent/EP4014971A1/en active Pending
- 2011-07-18 TW TW100125336A patent/TWI516477B/zh active
- 2011-07-18 LT LTEPPCT/US2011/044378T patent/LT2593090T/lt unknown
- 2011-07-18 CN CN202111624430.7A patent/CN114209699A/zh active Pending
- 2011-07-18 HU HUE11740764A patent/HUE057184T2/hu unknown
- 2011-07-18 KR KR1020227000133A patent/KR20220005631A/ko not_active Application Discontinuation
- 2011-07-18 CN CN2011800446021A patent/CN103221035A/zh active Pending
- 2011-07-18 KR KR1020217003243A patent/KR20210014770A/ko not_active Application Discontinuation
- 2011-07-18 PL PL11740764T patent/PL2593090T3/pl unknown
- 2011-07-18 MX MX2013000567A patent/MX336741B/es unknown
- 2011-07-18 EP EP11740764.3A patent/EP2593090B1/en active Active
- 2011-07-18 TW TW104132637A patent/TW201602083A/zh unknown
- 2011-07-18 NZ NZ607118A patent/NZ607118A/en unknown
- 2011-07-18 BR BR112013000980-2A patent/BR112013000980B1/pt active IP Right Grant
- 2011-07-18 US US13/810,537 patent/US9724342B2/en active Active
- 2011-07-18 EA EA201300146A patent/EA030435B1/ru active Protection Beyond IP Right Term
-
2013
- 2013-01-13 IL IL224189A patent/IL224189A/en active IP Right Grant
- 2013-01-17 ZA ZA2013/00458A patent/ZA201300458B/en unknown
-
2016
- 2016-05-06 JP JP2016093433A patent/JP6503317B2/ja active Active
- 2016-10-18 AU AU2016247044A patent/AU2016247044A1/en not_active Abandoned
-
2017
- 2017-02-07 US US15/426,804 patent/US10039757B2/en active Active
- 2017-06-02 US US15/612,703 patent/US10034873B2/en active Active
- 2017-07-05 IL IL253333A patent/IL253333A0/en unknown
-
2018
- 2018-07-03 US US16/026,708 patent/US10548888B2/en active Active
- 2018-08-22 AU AU2018220045A patent/AU2018220045B2/en active Active
-
2019
- 2019-03-25 JP JP2019056131A patent/JP2019142879A/ja not_active Withdrawn
- 2019-12-20 US US16/722,563 patent/US11123338B2/en active Active
-
2020
- 2020-06-03 AU AU2020203645A patent/AU2020203645A1/en not_active Abandoned
-
2021
- 2021-08-23 US US17/409,098 patent/US20210379050A1/en not_active Abandoned
- 2021-10-19 US US17/505,307 patent/US20220031688A1/en not_active Abandoned
- 2021-11-30 US US17/538,310 patent/US20220087999A1/en not_active Abandoned
-
2022
- 2022-07-20 US US17/869,427 patent/US20220370436A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL253333A0 (en) | Pharmaceutical preparations that modulate c-met | |
HK1246170A1 (zh) | 藥物組合物 | |
IL223535A (en) | Solid medicinal compositions | |
ZA201301766B (en) | Pharmaceutical compositions | |
IL225457A0 (en) | Pharmaceutical composition | |
ZA201207670B (en) | Pharmaceutical compositions | |
ZA201300718B (en) | Pharmaceutical compositions | |
ZA201303223B (en) | Pharmaceutical compositions | |
ZA201303177B (en) | Pharmaceutical compositions | |
IL226554A (en) | Medicinal preparations containing alisporiovir | |
GB201001911D0 (en) | Pharmaceutical composition | |
EP2560678A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
ZA201303732B (en) | Pharmaceutical compositions | |
GB201008590D0 (en) | Pharmaceutical compositions | |
GB201005403D0 (en) | Novel pharmaceutical compositions | |
GB201019775D0 (en) | Pharmaceutical composition |